Osteoarthritis

You have full text access to this OnlineOpen article

Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double-blind, placebo-controlled study†

  1. X. Chevalier1,‡,*,
  2. P. Goupille2,
  3. A. D. Beaulieu3,
  4. F. X. Burch4,
  5. W. G. Bensen5,§,
  6. T. Conrozier6,
  7. D. Loeuille7,
  8. A. J. Kivitz8,
  9. D. Silver9,
  10. B. E. Appleton10,¶

Article first published online: 26 FEB 2009

DOI: 10.1002/art.24096

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 61, Issue 3, pages 344–352, 15 March 2009

Additional Information

How to Cite

Chevalier, X., Goupille, P., Beaulieu, A. D., Burch, F. X., Bensen, W. G., Conrozier, T., Loeuille, D., Kivitz, A. J., Silver, D. and Appleton, B. E. (2009), Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double-blind, placebo-controlled study. Arthritis & Rheumatism, 61: 344–352. doi: 10.1002/art.24096

Author Information

  1. 1

    University Hospital, Créteil, France

  2. 2

    University of Tours, INSERM CIC-202, Tours, France

  3. 3

    Laval University, Quebec City, Quebec, Canada

  4. 4

    San Antonio Center for Clinical Research, San Antonio, Texas

  5. 5

    McMaster University and St. Joseph's Hospital, Hamilton, Ontario, Canada

  6. 6

    University of Lyon and INSERM CIC201, Lyon, France

  7. 7

    University Hospital, Nancy, France

  8. 8

    Altoona Arthritis & Osteoporosis Center, Duncansville, Pennsylvania

  9. 9

    Cedars-Sinai Hospital, Beverly Hills, California

  10. 10

    Amgen, Inc., Thousand Oaks, California

  1. ‡

    Dr. Chevalier has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Sankyo, Rottapharm, Expanscience, Pfizer, Genzyme, Servier, Fidia, and Negma.

  2. §

    Dr. Bensen has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Pfizer, Merck, Novartis, Procter & Gamble, Aventis, Amgen, Abbott, Roche, Schering-Plough, and Bristol-Meyers Squibb.

  3. Dr. Appleton owns stock and/or holds stock options in Amgen.

*Department of Rheumatology, Hospital Henri Mondor, University Paris XII, Paris (Créteil), France

  1. †

    ClinicalTrials.gov identifier: NCT00110916.

Publication History

  1. Issue published online: 26 FEB 2009
  2. Article first published online: 26 FEB 2009
  3. Manuscript Accepted: 6 NOV 2008
  4. Manuscript Received: 29 JUN 2008

Funded by

  • Amgen

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (181K)

REFERENCES

  • 1
    Anderson JJ, Felson DT. Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey (HANES I): evidence for an association with overweight, race, and physical demands of work. Am J Epidemiol 1988; 128: 179–89.
  • 2
    Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF. The prevalence of knee osteoarthritis in the elderly: the Framingham Osteoarthritis Study. Arthritis Rheum 1987; 30: 914–8.
    Direct Link:
  • 3
    Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 2000; 133: 635–46.
  • 4
    American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43: 1905–15.
    Direct Link:
  • 5
    Schnitzer TJ and the American College of Rheumatology. Update of ACR guidelines for osteoarthritis: role of coxibs. J Pain Symptom Manage 2002; 23: S24–30.
  • 6
    Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
  • 7
    Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005; 64: 669–81.
  • 8
    Cicuttini FM, Jones G, Forbes A, Wluka AE. Rate of cartilage loss at two years predicts subsequent total knee arthroscopy: a prospective study. Ann Rheum Dis 2004; 63: 1124–7.
  • 9
    Wluka AE, Ding C, Jones G, Cicuttini FM. The clinical correlates of articular cartilage defects in symptomatic knee osteoarthritis: a prospective study. Rheumatology (Oxford) 2005; 44: 1311–6.
  • 10
    Davies-Tuck ML, Wluka AE, Wang Y, Teichtahl AJ, Jones G, Ding C, et al. The natural history of cartilage defects in people with knee osteoarthritis. Osteoarthritis Cartilage 2008; 16: 337–42.
  • 11
    Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305–15.
    Direct Link:
  • 12
    Shingu M, Nagai Y, Isayama T, Naono T, Nobunaga M, Nagai Y. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993; 94: 145–9.
    Direct Link:
  • 13
    Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS, Woessner JR Jr. Evidence for metalloprotease and metalloprotease inhibitors imbalance in human osteoarthritic cartilage. J Clin Invest 1989; 84: 678–85.
  • 14
    Seckinger P, Klein-Nulend J, Alander C, Thompson RC, Dayer JM, Raisz LG. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol 1990; 145: 4181–4.
  • 15
    Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43: 1001–9.
    Direct Link:
  • 16
    Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase-1 expression. Arthritis Rheum 1996; 39: 1535–44.
    Direct Link:
  • 17
    Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997; 40: 1012–9.
    Direct Link:
  • 18
    Fernandes J, Tardif G, Martel-Pelletier J, Lascau-Coman V, Dupuis M, Moldovan F, et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999; 154: 1159–69.
  • 19
    Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005; 32: 1317–23.
  • 20
    Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29: 1039–49.
    Direct Link:
  • 21
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 1833–40.
  • 22
    Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004; 12: 389–99.
  • 23
    Hughes R, Carr A. A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology (Oxford) 2002; 41: 279–84.
  • 24
    Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113–23.
  • 25
    Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354: 795–808.
  • 26
    Altman RD, Moskowitz R, and the Hyalgan Study Group. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. J Rheumatol 1998; 25: 2203–12.
  • 27
    Altman RD, Akermark C, Beaulieu AD, Schnitzer T, and the Durolane International Study Group. Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee. Osteoarthritis Cartilage 2004; 12: 642–9.
  • 28
    Patient information: Kineret (anakinra). Thousand Oaks (CA): Amgen; 2006.
  • 29
    Vignon E, Balblanc JC, Mathieu P, Louisot P, Richard M. Metalloprotease activity, phospholipase A2 activity and cytokine concentration in osteoarthritic synovial fluid. Osteoarthritis Cartilage 1993; 1: 115–20.
  • 30
    Richette P, Francois M, Vicaut E, Bardin T, Fitting C, Cavaillon JM, et al. Assessment of the synovial fluid interleukin-1 receptor antagonist (IL-1Ra)/ interleukin-1 β (IL-1β) ratio in patients with osteoarthritis and rheumatoid arthritis [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S575.
View Full Article (HTML) Get PDF (181K)